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Abstract. Accumbal dopamine plays an important role in physiological responses and diseases 
such as schizophrenia, Parkinson’s disease, and depression. Since the nucleus accumbens contains 
different neurotransmitters, it is important to know how they interact with dopaminergic function: 
this is because modifying accumbal dopamine has far-reaching consequences for the treatment of 
diseases in which accumbal dopamine is involved. This review provides a summary of these inter-
actions, and our current knowledge about them are as follows: A) AMPA receptors are required 
for dopamine-dependent behavior and vice versa; NMDA receptors modulate the activity at the 
level of AMPA and/or dopamine D1 receptors. B) GABAA, but not GABAB, receptors inhibit 
 dopamine-dependent behavior. C) Nicotinic receptors are required for dopamine-dependent beha-
vior, whereas muscarinic receptors inhibit dopamine-dependent behavior. D) α-Adrenoceptors 
 inhibit dopamine-dependent behavior in contrast to β-adrenoceptors, which potentiate this  behavior. 
E) μ- and δ2-opioid receptors elicit behavior that requires an intact dopaminergic function and 
 δ2-opioid receptors modulate dopamine-dependent behavior. F) Orexin 2 receptors play an 
 important, modifying role in dopamine-dependent behavior. G) Somatostatin receptors potentiate 
dopamine-dependent behavior. It is suggested that modulation of the above-mentioned non- 
dopaminergic receptors provide new tools to control physiological functions as well as diseases 
mediated by accumbal dopamine.
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Critical Review
1. Introduction
Dopamine in the central nervous system plays an im-
portant role not only in behavior and physiological re-
sponses, but also in many diseases (review: 1; depression: 
2; drug addiction: 3 – 5; attention deficit hyperactivity 
disorder (ADHD): 6, 7; schizophrenia: 8, 9; Parkinson’s 
disease, review: 10). The nucleus accumbens (Nacc), 
which is a terminal area of the mesolimbic dopaminergic 
neurons, is known to be one of the main structures con-
trolling physiological responses, behavior, and diseases 
(1). The Nacc is a heterogeneous structure and is divided 
anatomically into at least two structures, that is, the shell 
and the core (11 – 14). There are many differences be-
tween these two structures. For instance, the dopamine 
plexus is richer in the shell than in the core (13), and the 
concentration of dopamine is higher in the shell than in 
the core (12). Furthermore, the dopamine D1 binding in 
the rostral areas of the Nacc appears to be higher in the 
shell than in the core, whereas the dopamine D2 binding Invited article
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appears to be lower in the shell than in the core (11). 
Thus, it is not remarkable that dopamine functions vary 
across the core and the shell (15, 16). The shell is thought 
to play a pivotal role in dopamine-mediated functions 
because it contains the largest amount of dopaminergic 
terminals and the highest concentration of dopamine (12, 
13).
Unilateral activation of the Nacc has been shown to 
elicit two characteristic types of turning behavior, namely 
circling and pivoting (16, 17). Circling is marked by 
normal hindlimb stepping, normal forelimb stepping, 
turns of large diameter (> 30 cm), and running, whereas 
pivoting is marked by abnormal hindlimb stepping, turns 
of small diameter (< 20 cm), and spinning around one 
hindlimb (17). More specifically, we have provided 
pharmacological evidence that unilateral stimulation of 
dopamine D1/D2 receptors in the Nacc shell, but not the 
Nacc core, elicits contraversive pivoting, whereas unilat-
eral stimulation of acetylcholine receptors in the Nacc 
shell elicits contraversive circling (15, 16). Since the 
contraversive pivoting induced by unilateral stimulation 
of dopamine D1/D2 receptors in the Nacc shell is a char-
acteristic feature of the function of accumbal dopamine 
in the Nacc shell and the contraversive circling induced 
by unilateral stimulation of acetylcholine receptors in the 
Nacc shell is a characteristic feature of the function of 
accumbal acetylcholine in the Nacc shell, these behaviors 
are very useful tools for studies on analysis of interac-
tions between various accumbal, neuroactive compounds 
as well as for studies on analysis of the involved output 
stations of the Nacc. We have provided evidence that the 
shell-specific, dopaminergic pivoting is mediated via a 
substrate that differs from that involved in the shell-
specific, cholinergic circling (16, 18 – 21).
The Nacc receives not only dopaminergic projections 
from the ventral tegmental area (VTA) and the substantia 
nigra pars compacta (SNc), but also many other neuronal 
projections releasing other neurotransmitters and neuro-
peptides (see below). It is important to know to what 
extent these neuroactive compounds direct the function 
of accumbal dopamine: this is because accumbal 
 dopamine has important therapeutic consequences for 
the treatment of diseases in which accumbal dopamine is 
involved. This review provides a summary of these inter-
actions. Since a single neurotransmitter or neuropeptide 
can act at distinct receptors, this review focuses on the 
involved receptors.
2. Interaction with dopamine in the Nacc
Because the Nacc receives a variety of neuronal pro-
jections, each releasing their own neurotransmitter and/
or neuropeptide, it is not surprising that mutual interac-
tions between dopamine and neurotransmitters such as 
glutamate, γ-aminobutyric acid (GABA), acetylcholine, 
noradrenaline, serotonin, and neuropeptides such as en-
kephalin, orexin, and somatostatin occur in the Nacc (see 
below). These interactions as revealed by studying how 
compounds that selectively interact with one of the vari-
ous accumbal, non-dopaminergic receptors influence the 
shell-specific, dopaminergic pivoting, are discussed be-
low. Recently, heterodimerization of dopamine receptors 
has been shown for both the D1/D5- and D2/D3/D4-receptor 
families, which couple positively and negatively, respec-
tively, to adenylyl cyclase (for reviews: 22, 23; see also: 
24). Notably, heterodimers are formed by D1 and adeno-
sine A1 receptors, D2 or D3 and adenosine A2 receptors, 
D2 and somatostatin SST5 receptors, and D2 and cannabi-
noid CB1 receptors. Further, D1, D2, and D3 receptors 
physically assemble into functional D1/D2, D1/D3, and 
D2/D3 heterodimers possessing binding and coupling 
profiles distinct from the respective monomers. By using 
different experimental approaches various groups have, 
in fact, demonstrated the existence of dopamine hetero-
dimers in both transfected cell systems and the striatum 
with peculiar pharmacological, signaling, and functional 
properties. The putative role of these heteromers in the 
physiological regulation of accumbal function is yet un-
known. For that reason, the role of these heteromers will 
not be discussed, although future research may show that 
these have a functional and therapeutic significance.
2.1. Glutamate
The Nacc receives glutamatergic inputs from several 
brain areas including the prefrontal cortex, amygdala, 
and hippocampus (25 – 27). Anatomical evidence indi-
cates that there are interactions between dopaminergic 
and glutamatergic inputs in the Nacc (28, 29). The iono-
tropic glutamate receptors are classified into three types, 
that is, N-methyl-D-aspartic acid (NMDA), α-amino-3-
hydro-5-methyl-4-isoxazolpropionic acid (AMPA), and 
kainate receptors (30). Glutamatergic agonists have been 
found to enhance dopamine release in the Nacc, possibly 
via non-NMDA receptors (31), whereas accumbal dopa-
mine has been found to increase extracellular glutamate 
levels in the Nacc (32). In behavioral studies, agonists of 
the glutamatergic ionotropic receptors, AMPA and 
NMDA receptors, have been found to stimulate locomo-
tor activity when injected into the Nacc, and drugs that 
inhibit dopaminergic neurotransmission have been found 
to inhibit these effects (33, 34). Thus, both accumbal 
glutamate and accumbal dopamine regulate motor 
function.
To analyze in more detail the functional interaction 
between glutamate and dopamine in the Nacc shell, we 
have examined the role of glutamate receptors in eliciting 
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the shell-specific, dopaminergic pivoting. Unilateral in-
jection of AMPA into the Nacc shell elicited contraver-
sive pivoting and this effect was inhibited by the AMPA-
receptor antagonist NBQX (1,2,3,4-tetrahydro-6-nitro-
2,3-dioxo-benzo[f]quinoxaline-7-sulfonamide), 
indicating that unilateral stimulation of AMPA receptors 
in the Nacc shell elicits contraversive pivoting, which 
pattern is identical to that induced by unilateral stimula-
tion of dopamine receptors in the Nacc shell (35). The 
contraversive pivoting induced by stimulation of AMPA 
receptors in the Nacc shell was inhibited by the dopamine 
D1/D2-receptor antagonist cis-(Z)-flupenthixol injected 
into the same area (35), indicating that the contraversive 
pivoting elicited by the stimulation of AMPA receptors 
in the Nacc shell requires intact dopaminergic neu-
rotransmission in this brain region. Since AMPA-receptor 
stimulation has been found to enhance extracellular 
 levels of dopamine in the Nacc (31), it has been sug-
gested that stimulation of presynaptic AMPA receptors 
on dopaminergic terminals elicits contraversive pivoting 
(31, 35). In this context, it has to be stated that the stimu-
latory effects of AMPA receptors on dopamine release in 
the Nacc are not necessarily due to direct actions of this 
excitatory amino acid on dopaminergic terminals: indi-
rect actions through intrinsic neurons or feedback loops 
cannot be excluded (36).
Stimulation or inhibition of NMDA receptors in the 
Nacc shell does not elicit turning behavior (35). The 
notion that NMDA receptors are not involved in this re-
spect fits in with the finding that there is no functional 
interaction between accumbal NMDA receptors and ac-
cumbal dopamine receptors. In fact, evidence is available 
that local application of NMDA does not affect dopamine 
release from the Nacc (31). However, the NMDA-recep-
tor antagonist MK-801 [(+)-5-methyl-10,11-dihydro-5H-
dibenzo[a,b]cyclohepten-5,10-imine)] has been found to 
inhibit dose-dependently the shell-specific, AMPA- 
induced pivoting when co-administered with AMPA into 
the Nacc shell (35), suggesting that NMDA receptors in 
the Nacc shell play a modulatory role in pivoting induced 
by unilateral injection of AMPA into the Nacc shell.
Contraversive pivoting induced by unilateral injection 
of a mixture of the dopamine D1-receptor agonist 
SKF 38393 and D2-receptor agonist quinpirole in the 
Nacc shell is inhibited by both MK-801 (Fig. 1A) and 
NBQX (Fig. 1B) injected into the same region (35). 
Thus, it has been concluded that the shell-specific, do-
paminergic pivoting requires intact glutamatergic neu-
rotransmission in the same region (35). This conclusion 
complements the earlier reported finding that locomotor 
activity produced by cocaine or dopamine D1/D2-receptor 
agonists are antagonized by intra-accumbens administra-
tion of AMPA- or NMDA-receptor antagonists (37, 38). 
It has been suggested that stimulation of presynaptic 
dopaminergic receptors on glutamatergic terminals elicits 
contraversive pivoting identical to that elicited by stimu-
lation of AMPA receptors in the Nacc shell (32, 35) 
 because accumbal dopamine is known to increase the 
release of accumbal glutamate (32).
Recently, it has been reported that NMDA receptors 
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Fig. 1. Inhibition of contraversive pivoting induced by a mixture of 
SKF 38393 and quinpirole injected into the nucleus accumbens shell 
by intra-shell injections of MK-801 (A), NBQX (B), muscimol (C), 
mecamylamine (D), and phenylephrine (E) or by intraperitoneal in-
jection of NTB (F). MK-801 (100 and 500 ng), NBQX (1 and 10 ng), 
muscimol (5 and 10 ng), mecamylamine (5 and 10 μg), and phen-
ylephrine (5 and 10 μg) were injected into the nucleus accumbens 
shell as a cocktail with a mixture of SKF 38393 (5 μg) and quinpirole 
(10 μg). NTB (1 and 3 mg/kg) were injected intraperitoneally 30 min 
before the injection of a mixture of SKF 38393 (5 μg) and quinpirole 
(10 μg) into the nucleus accumbens shell. The contraversive pivoting 
was measured soon after the injection of a mixture of SKF 38393 and 
quinpirole into the nucleus accumbens shell. *P < 0.05, **P < 0.01 
vs. SKF 38393 + quinpirole group.
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are localized on the neurons that contain dopamine D1 
receptors in the Nacc shell (39). Moreover, stimulation 
of dopamine D1 receptors in the Nacc shell phosphory-
lates AMPA receptors, thereby strengthening the function 
of AMPA receptors (40). Therefore, an alternative expla-
nation concerning the above-mentioned results is that 
NMDA and AMPA receptors postsynaptically modulate 
the dopamine function, possibly via D1 receptors.
The above-mentioned results indicate that 1) accumbal 
AMPA receptors direct the shell-specific, dopaminergic 
pivoting, 2) accumbal, dopamine D1/D2 receptors direct 
shell-specific, AMPA-mediated pivoting, and 3) accum-
bal NMDA receptors at best modulate the activity at the 
level of the involved accumbal AMPA and/or dopamine 
D1 receptors.
2.2. GABA
The Nacc contains two types of GABA receptors, 
namely GABAA and GABAB receptors (41). GABAA 
receptors have been found to inhibit accumbal dopamine 
release, although GABAB receptors are not devoid of a 
modulatory role in this respect (42).
There is a close relationship between GABAergic and 
dopaminergic systems in the Nacc in terms of regulating 
locomotor behavior. For example, GABAA-receptor 
 agonists reduce the hyperlocomotion induced by the 
 dopamine D1/D2-receptor agonist apomorphine (43, 44), 
whereas the GABAA-receptor antagonist picrotoxin en-
hances locomotor stimulant effects of dopamine-receptor 
agonists (43, 45). Recently, we have found that intra-
shell injection of muscimol, but not bicuculline, inhibits 
the contraversive pivoting induced by a mixture of 
SKF 38393 and quinpirole injected into the Nacc shell 
(Fig. 1C) and that this effect of muscimol is antagonized 
by bicuculline (46), indicating that this inhibitory effect 
of muscimol on the shell-specific, dopaminergic pivoting 
is GABAA-receptor specific. On the other hand, the shell-
specific, dopaminergic pivoting is also inhibited by 
baclo fen, but this effect of baclofen is not prevented by 
2-hydroxysaclofen (46), suggesting that the dopamine 
D1/D2 receptor–mediated pivoting is not mediated by 
GABAB receptors. Since stimulation of GABAA recep-
tors inhibits the dopamine release in the Nacc (42), the 
effect of muscimol is elicited via inhibition of endogenous 
dopamine release, which causes insufficient stimulation 
of dopamine D1/D2 receptors. Previously it has been 
shown that stimulation of D3 receptors (one of the D2-like 
receptors) reduces GABAA-receptor current through a 
phospho-dependent endocytosis mechanism in the Nacc 
(47). If the reduction of GABAA-receptor current induced 
by the stimulation of D3 receptors contributes to eliciting 
the shell-specific, dopaminergic pivoting, muscimol 
might strengthen the GABAA-receptor current and inhibit 
the shell-specific, dopaminergic pivoting.
In conclusion, GABAA, but not GABAB, receptors in 
the Nacc shell exert an inhibitory control upon the shell-
specific, dopaminergic pivoting (46).
2.3. Acetylcholine
As stated in the Introduction, unilateral activation of 
acetylcholine receptors in the Nacc shell predominantly 
elicits contraversive circling, whereas unilateral activa-
tion of dopamine D1/D2 receptors in the Nacc shell pre-
dominantly elicits contraversive pivoting (15, 16). Thus, 
these results have indicated that both acetylcholine and 
dopamine receptors in the Nacc shell play a crucial role 
in eliciting locomotor activity, but that there are subtle 
differences.
The available literature reveals that there is an interac-
tion between cholinergic and dopaminergic systems in 
the Nacc. For instance, stimulation of dopamine D1 re-
ceptors has been found to increase acetylcholine release 
in the Nacc, whereas stimulation of dopamine D2 recep-
tors has been found to inhibit acetylcholine release in 
the Nacc (48, 49). These data suggest that dopamine D1 
receptors exert an excitatory control on the cholinergic 
neurons in contrast to dopamine D2 receptors that exert 
an inhibitory control on these neurons. On the other hand, 
a muscarinic acetylcholine–receptor antagonist has been 
found to increase dopamine release in the Nacc, whereas 
a muscarinic acetylcholine–receptor agonist has been 
found to inhibit the increase of dopamine release induced 
by amphetamine (50) or by electric stimulation (51), 
suggesting that muscarinic acetylcholine receptors exert 
an inhibitory control on the dopaminergic neurons in the 
Nacc. Moreover, a nicotinic acetylcholine–receptor ago-
nist has been found to increase dopamine release in the 
Nacc (52), suggesting that nicotinic acetylcholine recep-
tors exert an excitatory control on the dopaminergic 
neurons.
In line with the above-mentioned neurochemical find-
ings, it has been found that the nicotinic acetylcholine–
receptor antagonist mecamylamine significantly sup-
presses the contraversive pivoting induced by the mixture 
of SKF 38393 and quinpirole injected into the Nacc shell 
(Fig. 1D) (29), suggesting that accumbal, nicotinic ace-
tylcholine receptors indeed exert an excitatory control on 
shell-specific, dopaminergic-dependent behavior as sug-
gested by the above-mentioned neurochemical studies. 
Since nicotinic acetylcholine receptors are both presyn-
aptically and postsynaptically localized in the Nacc (53), 
it cannot be excluded that the effect of mecamylamine is 
just mediated via an enhanced dopamine release. Re-
cently, nicotinic acetylcholine receptors in the Nacc shell 
have been reported to form complexes with presynaptic 
dopamine D2 receptors; stimulation of these nicotinic 
156 H Ikeda et al
receptors has been found to increase dopamine level (54). 
In contrast, postsynaptic, nicotinic acetylcholine recep-
tors are known to facilitate the GABA-mediated inhibi-
tion of the output neurons from the Nacc (53). There is 
evidence that the contraversive pivoting induced by the 
stimulation of dopamine D1/D2 receptors in the Nacc 
shell is funneled via GABAergic neurons innervating the 
SNc (15, 18, 21) and that GABAergic neurons from the 
Nacc to the SNc are inhibited by the stimulation of 
 dopamine D1/D2 receptors in the Nacc shell (15). On the 
basis of these data, it has been suggested that the meca-
mylamine’s inhibitory effects on dopaminergic function 
are at least partly induced by disinhibition of the 
GABAergic output neurons from the Nacc shell (53, 
55).
The muscarinic acetylcholine–receptor antagonist 
methylscopolamine significantly increases the contraver-
sive pivoting induced by a mixture of SKF 38393 and 
quinpirole injected into the Nacc shell (Fig. 2A) (55), 
suggesting that the muscarinic acetylcholine receptors 
indeed exert an inhibitory control on the shell-specific, 
dopamine-dependent behavior as suggested by the 
above-mentioned neurochemical studies. Given the find-
ings that a muscarinic acetylcholine–receptor antagonist 
increases dopamine release in the Nacc (50) and musca-
rinic acetylcholine receptors inhibit dopamine D1-receptor 
signaling in Nacc (56), it has been hypothesized that 
methylscopolamine potentiates the dopaminergic pivot-
ing by 1) a methylscopolamine-mediated enhancement 
of dopamine release in the Nacc shell, and by 2) a 
methylscopolamine-mediated disinhibition of dopamine 
D1-receptor signaling in the Nacc shell (50, 55, 56).
In contrast to the cholinergic influence on the shell-
specific, dopamine-dependent behavior, dopamine D1/D2 
receptors appear to exert no influence on accumbal, 
acetylcholine-dependent behavior. Thus, it has been 
found that inhibition of dopamine D1 and/or D2 receptors 
does not affect the contraversive circling elicited by 
unilateral administration of the acetylcholine-receptor 
agonist carbachol into the Nacc shell (55). To what extent 
these data really indicate that there is no influence of 
dopamine receptors on the function mediated by cholin-
ergic receptors remains open for discussion because the 
above-mentioned neurochemical studies have revealed 
that dopamine D1 and D2 receptors exert an excitatory 
and inhibitory control on the cholinergic neurons, 
respectively.
The available information has led to the conclusion 
that stimulation of nicotinic acetylcholine receptors in 
the Nacc shell is required for the shell-specific, dopamine-
dependent behavior and that, in contrast, muscarinic 
acetylcholine receptors in the Nacc shell inhibit the pro-
duction of the shell-specific, dopamine-dependent be-
havior (55).
2.4. Noradrenaline
The Nacc shell receives noradrenergic projections 
mainly from the nucleus tractus solitaries and the locus 
coeruleus (57). Previous studies have revealed that nor-
adrenaline can functionally influence dopamine in the 
Nacc (58; for review: 59, 60). For example, stimulation 
of α-adrenoceptors has been found to decrease dopamine 
release in the Nacc, whereas stimulation of 
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Fig. 2. Potentiation of contraversive pivoting induced by a mixture 
of SKF 38393 and quinpirole injected into the nucleus accumbens 
shell by intra-shell injections of methylscopolamine (A), isoprenaline 
(B), orexin A (C), orexin B (D), and somatostatin (E). Methylscopol-
amine (1 and 2.5 μg), isoprenaline (0.5 and 1 μg), orexin A (1 and 2 
μg), orexin B (0.5 and 1 μg), and somatostatin (0.5 and 1 μg) were 
injected into the nucleus accumbens shell as a cocktail with a mixture 
of SKF 38393 (1 μg) and quinpirole (10 μg). The contraversive pivot-
ing was measured soon after the drug injections. *P < 0.05, **P < 0.01 
vs. SKF 38393 + quinpirole group.
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β-adrenoceptors has been found to increase dopamine 
release in the Nacc (58, 61). Thus, these results suggest 
that α- and β-adrenoceptors exert an inhibitory and an 
excitatory control on dopamine release in the Nacc, 
respectively.
To determine the functional interaction between 
adrenergic and dopaminergic receptors in the Nacc shell, 
we have analyzed the role of α- and β-adrenoceptors in 
the Nacc shell in rat turning behavior. The local admin-
istration of neither α- nor β-adrenoceptor agonists and 
antagonists elicits turning behavior (62). As described 
above, although a β-adrenoceptor agonist increases do-
pamine release in the Nacc (58, 61), it cannot elicit 
turning behavior. The following possibilities may explain 
this discrepancy. One is that simultaneous stimulation of 
both dopamine D1 and D2 receptors in the Nacc shell 
elicits contraversive pivoting, but that stimulation of only 
one type of dopamine receptors does not elicit turning 
behavior (17). If increased dopamine stimulates either D1 
or D2 receptors, it cannot elicit turning behavior. Another 
possibility is the localization of receptors in the Nacc 
shell. We have already reported that there are at least two 
distinct pathways involved in the production of pivoting, 
namely the shell-ventral pallidum pathway that mediates 
locomotor activity and the accumbens–nigra–striatum 
pathway that mediates asymmetry (15, 17, 21). If other 
neurotransmitters affect just one dopaminergic pathway, 
they cannot elicit turning behavior.
Unilateral injection of the α-adrenoceptor agonist 
phenylephrine into the Nacc shell dose-dependently in-
hibited contraversive pivoting induced by a mixture of 
SKF 38393 and quinpirole into the Nacc shell (Fig. 1E) 
(62). This effect of phenylephrine was antagonized by 
phentolamine, which alone did not affect the dopaminer-
gic pivoting. Therefore, it can be concluded that the 
 inhibitory effect of phenylephrine on the dopaminergic 
pivoting is α-adrenoceptor-specific within the Nacc shell. 
The fact that α-adrenoceptors inhibit dopaminergic 
 pivoting might be explained by presynaptic and/or post-
synaptic mechanisms. As mentioned above, stimulation 
of α-adrenoceptors inhibits dopamine release in the 
Nacc (58, 60). This outcome implies that stimulation of 
accumbal dopamine D1/D2 receptors by means of 
SKF 38393 and quinpirole elicits pivoting only when the 
baseline tonus at one or both subtypes of these dopamine 
receptors is already high. Since stimulation of dopamine 
D1 receptors by means of endogenous dopamine has been 
found to be necessary for the display of behavior elicited 
by stimulation of dopamine D2 receptors (63), it is 
thought that the baseline tonus is high, especially at the 
level of the dopamine D1 receptors. Accordingly, it is 
attractive to postulate that accumbal α-adrenoceptors 
control at least accumbal dopamine D1 receptors.
We have shown that the β-adrenoceptor agonist iso-
prenaline injected into the Nacc shell dose-dependently 
potentiated the contraversive pivoting induced by a 
mixture of SKF 38393 and quinpirole injected into the 
Nacc shell (Fig. 2B) (62); the effect of isoprenaline was 
antagonized by a dose of propranolol that per se had no 
effect on this pivoting, indicating that the potentiating 
effect of isoprenaline is β-adrenoceptor-specific (62). 
These data agree with the findings from neurochemical 
studies showing that stimulation of β-adrenoceptors in-
creases dopamine release in the Nacc shell (62). All these 
data indicate that α-adrenoceptors in the Nacc shell exert 
an inhibitory effect on the shell-specific, dopaminergic 
pivoting in contrast to β-adrenoceptors in the Nacc shell, 
which exert a stimulatory effect on shell-specific do-
paminergic pivoting (for references, see above).
2.5. Serotonin
Serotonin (5-HT) receptors are widely distributed in 
the brain (64). There are many reports indicating that the 
serotonergic system modulates dopamine function in the 
brain. However, most reports focused on the interaction 
between 5-HT and dopamine in the VTA, since serotonin 
neurons project from the dorsal and medial raphe nuclei 
to the VTA (65). In fact, injection of 5-HT into the VTA 
increases dopamine level in the Nacc (66). The interac-
tion between 5-HT and dopamine in the Nacc has also 
been reported. The 5-HT1B-receptor agonist increases 
dopamine level in the Nacc (67). Moreover, 5-HT2C- 
receptor antagonists inhibit cocaine-induced dopamine 
release in the Nacc (68). In the behavioral studies, the 
injection of 5-HT2C-receptor agonist potentiates cocaine-
induced behavior (69). More specifically, injection of 
5-HT1B-receptor agonist and antagonist into the Nacc 
shell potentiates and inhibits cocaine-induced locomotor 
activity, respectively, whereas the same drug injected 
into the Nacc core is without effect (70). Since the reports 
examining the role of the serotonergic system in the Nacc 
shell and core are limited and there are many subtypes of 
5-HT receptors, further studies are needed to clarify the 
role of the serotonergic system in modulating accumbal 
dopamine functions.
2.6. Opioid
Opioid receptors (i.e., μ-, δ-, and κ-opioid receptors) 
have been reported to regulate mesolimbic dopaminergic 
neuronal activities. For example, activation of μ-opioid 
receptors by intra-cerebral administration of the agonists 
fentanyl and [D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin 
(DAMGO) (VTA: 71, Nacc: 72) and δ-opioid receptors 
by means of the agonists deltorphin II and [D-Pen2,5]-
enkephalin (DPDPE) given into the Nacc (72, 73) en-
hances extracellular dopamine concentration in the Nacc, 
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whereas activation of κ-opioid receptors by means of the 
agonist U69593 given into the Nacc decreases dopamine 
concentration in the Nacc (74). The involved receptors 
are thought to be located in the VTA (for μ-opioid recep-
tors) and the Nacc (for μ-, δ-, and κ-opioid receptors).
Stimulation of μ-opioid receptors in the VTA has been 
found to increase locomotor activity (75, 76). This effect 
is considered to be dopamine-dependent because it does 
not occur in 6-hydroxydopamine (6-OHDA)-lesioned 
animals (76). In contrast, hyperlocomotion induced by 
μ-opioid receptor stimulation in the Nacc is unaffected 
by dopamine depletion (75, 77). A similar hyperlocomo-
tion induced by δ-opioid receptor stimulation in the Nacc 
is also unaffected by dopamine depletion (73, 77). There-
fore, the enhanced locomotor activity induced by injec-
tions of μ- and δ-opioid receptor agonists into the Nacc 
is thought to be dopamine-independent. However, be-
cause 6-OHDA-lesioned animals were used in the latter 
studies, compensatory changes in the Nacc may have 
affected the results. This probably explains why these 
behavioral results are contradictory to the results of the 
above-mentioned neurochemical studies.
We have examined the role of opioid receptors in the 
Nacc shell in eliciting dopamine-dependent behavior. 
Unilateral injections of DAMGO and deltorphin II, but 
not DPDPE, into the Nacc shell significantly elicited 
contraversive pivoting (78). The pivoting induced by 
DAMGO and deltorphin II was receptor-specific because 
each behavioral response was significantly inhibited by 
the μ-opioid receptor antagonist D-Phe-Cys-Tyr-D-Trp-
Orn-Thr-Phe-Thr-NH2 (CTOP) and the δ2-opioid receptor 
antagonist naltriben (NTB), respectively (78). The phe-
notype of this contraversive pivoting was similar to that 
elicited by unilateral injection of a mixture of SKF 38393 
and quinpirole into the Nacc shell (see also 15, 16, 21). 
In fact, the contraversive pivoting elicited by stimulation 
of μ- or δ2-opioid receptors in the Nacc shell was signifi-
cantly inhibited by cis-(Z)-flupenthixol injected into the 
Nacc shell (78). These results allow the conclusion that 
the μ- and δ2-opioid receptor–mediated effects require an 
intact dopaminergic system. This fits in with our earlier 
published data that local applications of these opioid re-
ceptor agonists (i.e., DAMGO and deltorphin II) enhance 
extracellular levels of dopamine in the Nacc (72). Thus, 
it is likely that both μ- and δ2-opioid receptors are presyn-
aptically localized on dopaminergic neurons that mediate 
the dopaminergic pivoting.
Despite the fact that stimulation of δ1-opioid receptors, 
like stimulation of μ- and δ2-opioid receptors, enhances 
the release of accumbal dopamine (72), such stimulation 
did not elicit pivoting (78). A possible explanation for 
this finding is that the δ1-opioid receptors, in contrast to 
the μ- and δ2-opioid receptors, are localized on dopamin-
ergic terminals that are not involved in the production of 
pivoting. Indeed, there are at least two distinct neuronal 
pathways involved in the production of pivoting, namely 
the shell–ventral pallidum pathway that mediates loco-
motor activity and the accumbens–nigra–striatum path-
way that mediates asymmetry (17; see also 16, 21). In 
view of these considerations, it has been hypothesized 
that a) μ- and δ2-opioid receptors are presynaptically 
 localized on dopaminergic neurons that impinge on both 
the shell–ventral pallidum pathway and the accumbens–
nigra–striatum pathway, and that b) δ1-opioid receptors 
are at best presynaptically localized on dopaminergic 
neurons that impinge just on the accumbens–nigra–stria-
tum pathway (72, 73, 78). An alternative explanation for 
the ineffectiveness of the δ1-opioid receptor agonist 
might be that the DPDPE-induced increase of extracel-
lular dopamine is due not to stimulation of δ1-opioid 
 receptors, but to stimulation of opioid-independent 
mechanisms.
It has been found that contraversive pivoting induced 
by a mixture of SKF 38393 and quinpirole into the Nacc 
shell is also inhibited by NTB (Fig. 1F), but not by CTOP 
or the δ1-opioid receptor antagonist (E)-7-benzyliden-
naltrexone (BNTX) (78). These results therefore suggest 
that δ2-, but not μ- and δ1-, opioid receptors interact with 
postsynaptically localized dopamine D1/D2-receptor 
mechanisms involved in the production of pivoting.
These results demonstrate that unilateral stimulations 
of μ- or δ2-opioid receptors, but not δ1-opioid receptors, 
in the Nacc shell elicit contraversive pivoting that re-
quires intact dopamine D1/D2-receptor mechanisms in 
the Nacc shell. Moreover, it has been shown that the 
shell-specific, dopaminergic pivoting is modulated by 
δ2-, but not μ- and δ1-, opioid receptors.
2.7. Orexin
Orexins (orexin A and B) are peptides, which were 
originally isolated from rat hypothalamus (79). Because 
the hypothalamus is the regulatory center for autonomic 
and endocrine homeostatic systems, orexins are thought 
to regulate such systems including feeding behavior, 
arousal activity, and arterial pressure (79 – 81). Orexin 
neurons and orexin receptors are not only present in the 
hypothalamus, but also extensively distributed across 
various brain areas (82, 83). This may imply that these 
peptides play an important role in several physiological 
functions.
Previously, it has been reported that orexin neurons 
originating in the lateral hypothalamus impinge upon 
dopaminergic cells in the VTA (84 – 86). Orexins in-
jected into the VTA activate dopaminergic neurons (86). 
These results indicate that stimulation of orexin receptors 
in the VTA activates dopamine neurons and, accordingly, 
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increases dopamine release in the Nacc (86), and, subse-
quently, increases locomotor activity.
Since the Nacc has been found to contain mRNA for 
both orexin 1 receptors and orexin 2 receptors (83), we 
examined the role of orexin receptors in dopamine- 
dependent behavior. Orexin A injected into the Nacc 
shell significantly potentiated the contraversive pivoting 
induced by a mixture of SKF 38393 and quinpirole in-
jected unilaterally into the Nacc shell (Fig. 2C) (87). The 
potentiating effect of orexin A was not antagonized by 
the orexin 1-receptor antagonist SB 334867, which alone 
did not significantly modify the contraversive pivoting 
induced by the mixture of SKF 38393 and quinpirole 
injected unilaterally into the Nacc shell (87). Our result 
indicates that the effect of orexin A was not mediated via 
orexin 1 receptors in the Nacc shell. Since orexin A is 
equipotent at orexin 1 and 2 receptors, we have examined 
the role of orexin 2 receptors in dopaminergic pivoting. 
The orexin 2 receptor–selective agonist orexin B injected 
into the Nacc shell significantly potentiated the contra-
versive pivoting induced by the mixture of SKF 38393 
and quinpirole injected unilaterally into the Nacc shell 
(Fig. 2D) (87). This result shows that orexin 2 receptors 
play an important, modifying role in eliciting the shell-
specific, dopaminergic pivoting. This conclusion is sup-
ported by the recent report that orexin B and dopamine 
synergistically increases the firing rate of neurons in the 
Nacc shell (88).
Previous reports have indicated that the cell bodies of 
dopaminergic neurons in the VTA are innervated by 
orexin neurons originating in the lateral hypothalamus 
and that stimulation of orexin receptors in the VTA acti-
vates dopamine neurons (84 – 86). Since the injection of 
orexin A into the VTA is reported to be more effective in 
eliciting hyperlocomotion than that of orexin B (85, 86), 
it has been suggested that orexin 1 receptors, but not 
orexin 2 receptors, in the VTA stimulate dopaminergic 
neurons. Our results demonstrate that orexin 2 receptors 
in the Nacc shell, which is the terminal area of dopamine 
neurons originating in the VTA, also modulate the func-
tion mediated by accumbal dopamine. These data are in 
line with the previously reported finding that the expres-
sion of orexin 2-receptor mRNA in the Nacc is greater 
than that of orexin 1-receptor mRNA in the Nacc (83). 
Thus, different subtypes of orexin receptors, that is, 
orexin 1 and 2 receptors, modulate dopaminergic func-
tion in the VTA and the Nacc, respectively.
2.8. Somatostatin
Somatostatin is a tetradecapeptide that was originally 
isolated from mammalian hypothalamus and character-
ized as a potent physiological inhibitor of growth hor-
mone secretion from the anterior pituitary (89). Soma-
tostatin and its receptors are not only present in the 
hypothalamus, but also widely distributed across the 
central nervous system (90, 91). Since the striatum and 
Nacc are reported to contain both somatostatin and its 
receptors (90, 92), it is possible that somatostatin regu-
lates dopaminergic function in these brain areas.
Many neurochemical and behavioral studies on the 
functional role of somatostatin in the striatum have been 
reported. In neurochemical studies, systemic or intra-
striatal injection of somatostatin or a somatostatin-recep-
tor agonist increases dopamine release in the striatum 
(93). These results indicate that somatostatin positively 
regulates dopamine release in the striatum. Conversely, 
dopamine also regulates somatostatin level in the stria-
tum (94, 95). For example, dopamine-receptor antago-
nists such as haloperidol reduce somatostatin-like im-
munoreactivity in the striatum (94). Moreover, dopamine 
D1- and D2-receptor agonists potentiate the effects of 
somatostatin on somatostatin-receptor binding, inhibition 
of adenylyl cyclase activity, and accumulation of inositol 
1,4,5-trisphosphate (95). In behavioral studies, soma-
tostatin in the striatum has also been found to play a regu-
latory role in dopamine-dependent behavior. Intra-striatal 
injection of cysteamine, which selectively reduces soma-
tostatin levels, blocks apomorphine-induced stereotypy 
(96). These neurochemical and behavioral findings show 
that somatostatin in the striatum plays an important role 
in dopaminergic functions.
In contrast to the striatum, the role of somatostatin in 
the Nacc has received less attention. Neurochemical 
studies have indicated that the perfusion of somatostatin 
into the Nacc increases dopamine release in the same 
area (97). To determine the function of accumbal soma-
tostatin on dopamine-dependent behavior, we examined 
the role of somatostatin on dopamine-dependent behav-
ior. Somatostatin significantly potentiated the contraver-
sive pivoting induced by the mixture of SKF 38393 and 
quinpirole unilaterally injected into the Nacc shell (Fig. 
2E) (98). This potentiating effect of somatostatin was 
significantly antagonized by the somatostatin-receptor 
antagonist cyclosomatostatin, which alone did not sig-
nificantly modify the contraversive pivoting induced by 
the mixture of SKF 38393 and quinpirole injected unilat-
erally into the Nacc shell (99). Somatostatin has been 
reported to increase dopamine release in the Nacc (97). 
Moreover, in the striatum, somatostatin increases do-
pamine release via the glutamatergic system, especially 
via AMPA and NMDA receptors (93). We have shown 
that the shell-specific, dopaminergic pivoting is mediated 
by both AMPA and NMDA receptors in the same area 
(see above and ref. 35). Therefore, one can speculate that 
somatostatin increases dopamine release via the gluta-
matergic system, including AMPA and NMDA receptors, 
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in the Nacc shell. Another possibility is that somatostatin 
increases dopamine release caused by inhibiting GABA 
release, since somatostatin has been found to regulate 
GABA release presynaptically in the striatum (99). Thus, 
the potentiating effect of somatostatin on the contraver-
sive pivoting induced by dopamine D1/D2-receptor stimu-
lation in the Nacc shell may be due to additional stimula-
tion of dopamine D1 and D2 receptors caused by increased 
dopamine. It is also possible that somatostatin regulates 
dopamine-receptor functions postsynaptically in the po-
tentiating effect of somatostatin because dopamine and 
somatostatin-receptor activation may work in a co-oper-
ative manner on postsynaptic sites, possibly via second 
messenger pathways or common targets (100).
3. Conclusion
The present study focused on the modulation of the 
shell-specific, dopaminergic pivoting by glutamate, 
GABA, noradrenaline, acetylcholine, opioid, orexin, and 
somatostatin in the Nacc shell: these modulations vary 
across the different neurotransmitters, neuropeptides, 
and their corresponding receptors (Table 1). It has been 
shown that the dopaminergic pivoting is funneled from 
the Nacc shell via the SNc, the ventrolateral striatum, and 
the substantia nigra pars reticulata towards the peduncu-
lopontine tegmental nucleus (15, 18, 21). Thus, this 
pathway is likely to be controlled by these neurotransmit-
ters in the Nacc shell, implying that all functions medi-
ated via this pathway are sensitive to modulation by 
compounds that selectively interact with one or more of 
these neuroactive compounds. As mentioned above, the 
shell-specific, dopaminergic pivoting is just used as a 
tool to trace the nature of the interactions of dopamine 
with other neuroactive compounds and vice versa as well 
as a tool to trace the pathways involved in the transmis-
sion of accumbal dopamine–dependent information 
across the brain: it has no face validity with any of the 
known functions of accumbal dopamine. Given the well-
known therapeutic effects of drugs that enhance accumbal 
dopamine, in patients suffering from depression, ADHD 
or Parkinson’s disease, agents that directly or indirectly 
stimulate the activity at the level of the receptors shown 
in Table 1, are predicted to have a therapeutic efficacy as 
well. On the other hand, it is predicted that agents that 
directly or indirectly inhibit the activity at the level of the 
receptors shown in Table 1, are therapeutically effective 
in patients suffering from schizophrenia, because drugs 
that reduce the accumbal dopaminergic activity in such 
patients are therapeutically effective. The putative 
 advantage of using drugs that indirectly alter the activity 
at the level of the accumbal dopamine receptors is that 
Table 1. Summary of the role of each neuroactive compound on accumbens-specific behavior
Production of 
turning behavior
Modulation of 
dopamine-dependent 
turning behavior
Glutamate receptors 
NMDA* − ↑
AMPA* ↑ ↑
GABA receptors 
GABAA − ↓
GABAB − −
Acetylcholine receptors 
muscarine ↑ ↓
nicotine ↑ ↑
Adrenaline receptors 
α − ↓
β − ↑
Serotonin receptors 
5-HT1B − ↑
5-HT2C − ↑
Opioid receptors 
μ ↑ −
δ1 − −
δ2 ↑ ↑
Orexin receptors 
orexin 1 − −
orexin 2 − ↑
Somatostatin receptors − ↑
*Stimulation indirectly affects accumbal dopamine-dependent pivoting. Up arrow: increases 
 behavior, down arrow: decreases behavior.
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such drugs do not alter the sensitivity of the involved 
dopamine receptors and, therefore, result in less unwanted 
side-effects than drugs that directly affect the dopamine 
receptors.
In conclusion, since both accumbal dopamine, as well 
as the above-mentioned pathway, play a crucial role in a 
great variety of neurological and psychiatric diseases 
such as depression, drug addiction, ADHD, schizophre-
nia, and Parkinson’s disease, it is suggested that drugs 
that selectively interfere with one or more of these non-
dopaminergic compounds, are promising candidates for 
treating these diseases.
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